Champions Oncology Q4 Adj EPS $(0.17) Misses $(0.12) Estimate, Sales $13.07M Beat $12.86M Estimate
Portfolio Pulse from sunil@benzinga.com
Champions Oncology (NASDAQ:CSBR) reported Q4 losses of $(0.17) per share, missing the analyst consensus estimate of $(0.12) by 41.67%. This is a 750% decrease from the same period last year. However, the company's quarterly sales of $13.07 million beat the analyst consensus estimate of $12.86 million by 1.64%, a 1.51% increase from last year.
July 24, 2023 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Champions Oncology's Q4 earnings per share missed estimates by 41.67%, but sales beat estimates by 1.64%.
Champions Oncology's Q4 earnings per share missed the analyst consensus estimate by a significant margin, which could negatively impact investor sentiment and the stock price. However, the company's sales beat estimates, which could offset some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100